Meta-analysis: Second generation antidepressants and headache

Telang, Shilpa; Walton, Celeste; Olten, Baris; Bloch, Michael H.

doi:10.1016/j.jad.2018.04.047

Cited by 21 publications

(8 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is often difficult to differentiate treatment-emergent somatic symptoms from adverse effects of antidepressants. The antidepressants that commonly cause headache are SSRIs and serotonin noradrenaline reuptake inhibitors, especially bupropion and escitalopram 45. A point worth mentioning is premenstrual syndrome/premenstrual dysphoric disorder is often regarded as an implication of bipolar disorder 46.…”

Section: Discussionmentioning

confidence: 99%

<p>Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study</p>

Yuan

Zhu

Luo

et al. 2019

NDT

View full text Add to dashboard Cite

Purpose Early improvement in major depressive disorder is defined as a reduction of ≥20% in the 17-item Hamilton Depression Rating Scale (HAM-D-17) score at the second week after initiation of treatment, predicting long-term treatment response. However, there remains no effective strategy for switching medications when a patient fails to reach early improvement at the second week. This study focused on the predictive value of early symptom changes in each item of the HAM-D-17 scale for treatment response to selective serotonin reuptake inhibitor (SSRI) monotherapy and to provide a reference for switching antidepressants to enhance early treatment efficacy. Patients and methods Our study was an observational, real-world study that enrolled 90 treatment-naïve patients experiencing their first episode of major depressive disorder in the outpatient department of Huashan Hospital. Patients who did not achieve the threshold of early improvement in the second week after starting treatment were switched to alternative SSRI monotherapy. Patient follow-up occurred at 2, 4, 8, and 12 weeks after the initiation of treatment. We analyzed the relationship between the change in each symptom on the HAM-D-17 scale and treatment efficacy. Results Early improvement predicted the treatment response at 12 weeks ( χ 2 =19.249, P <0.001), whereas early non-improvement in insomnia and anxiety was associated with a poor response (OR =9.487, 95% CI: 1.312–68.588 and OR =12.947, 95% CI: 1.99–82.246, respectively). At week 2, general somatic symptom aggravation was associated with a poorer response (OR =73.337, 95% CI: 2.232->999.999); treatment-emergent headache and tremor were associated with treatment efficacy (t=−9.521, P <0.001 and t=3.660, P =0.001, respectively). In addition, the increase in suicidal thoughts, once treatment began, had no relationship with the treatment response (OR =0.821, P =0.872). Conclusion This study suggested that patients with early non-improvement in insomnia and anxiety were not suitable for switches in SSRI monotherapy. Patients with treatment-emergent symptoms, especially headaches and tremors, were not suitable for switching from monotherapy to another SSRI.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study</p>

Yuan

Zhu

Luo

et al. 2019

NDT

View full text Add to dashboard Cite

show abstract

“…Outside of chronic pain, there is an interest in the use of SNRIs-apart from milnacipran-in the treatment of conditions such as fibromyalgia, although results have been mixed [98]. SNRIs as a prophylactic migraine therapy has also been an area of active research, however current results are inconclusive [99][100][101].…”

Section: Emerging Applicationsmentioning

confidence: 99%

New Serotonin-Norepinephrine Reuptake Inhibitors and Their Anesthetic and Analgesic Considerations

Fanelli

Weller

Liu

2021

Neurology International

View full text Add to dashboard Cite

Serotonin-norepinephrine reuptake inhibitors (SNRIs) inhibit the presynaptic neuronal uptake of serotonin and norepinephrine and prolong the effects of the monoamines in the synaptic cleft within the central nervous system, leading to increased postsynaptic receptor activation and neuronal activities. Serotonin-norepinephrine reuptake inhibitors can have multiple clinical indications, including as the first-line agents for the management of depression and anxiety, and as analgesics in the treatment of chronic pain. The effects of reuptake inhibition of norepinephrine and serotonin are often dose-dependent and agent-dependent. There are five FDA-approved serotonin-norepinephrine reuptake inhibitors (desvenlafaxine, duloxetine, levomilnacipran, milnacipran and sibutramine) currently being marketed in the United States. As the COVID-19 pandemic significantly increased the incidence and prevalence of anxiety and depression across the country, there are significantly increased prescriptions of these medications perioperatively. Thus, anesthesiologists are more likely than ever to have patients administered with these agents and scheduled for elective or emergency surgical procedures. A thorough understanding of these commonly prescribed serotonin-norepinephrine reuptake inhibitors and their interactions with commonly utilized anesthetic agents is paramount. There are two potentially increased risks related to the continuation of SNRIs through the perioperative period: intraoperative bleeding and serotonin syndrome. SNRIs have some off-label uses, more new indications, and ever-increasing new applications in perioperative practice. This article aims to review the commonly prescribed serotonin-norepinephrine reuptake inhibitors and the current clinical evidence regarding their considerations in perioperative anesthesia and analgesia.

show abstract

“…Individuals may consider psychotherapy instead of pharmaceutical treatment, due to possible side effects and potential dependence on medication[ 11 - 13 ]. Cognitive behavioural therapy (CBT) has been substantially confirmed to be an effective psychosocial treatment in managing depression and anxiety[ 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Effects of mindfulness-based intervention programs on sleep among people with common mental disorders: A systematic review and meta-analysis

Chan¹,

Lui²,

Chan³

et al. 2022

WJP

View full text Add to dashboard Cite

BACKGROUND Sleep problems are particularly prevalent in people with depression or anxiety disorder. Although mindfulness has been suggested as an important component in alleviating insomnia, no comprehensive review and meta-analysis has been conducted to evaluate the effects of different mindfulness-based intervention (MBI) programs on sleep among people with depression or anxiety disorder. AIM To compare the effects of different MBI programs on sleep among people with depression or anxiety disorder. METHODS Related publications in Embase, Medline, PubMed and PsycINFO databases were systematically searched from January 2010 to June 2020 for randomised controlled trials. Data were synthesized using a random-effects or a fixed-effects model to analyse the effects of various MBI programs on sleep problems among people with depression or anxiety disorder. The fixed-effects model was used when heterogeneity was negligible, and the random-effects model was used when heterogeneity was significant to calculate the standardised mean differences (SMDs) and 95% confidence intervals (CIs). RESULTS We identified 397 articles, of which 10 randomised controlled trials, involving a total of 541 participants, were included in the meta-analysis. Studies of internet mindfulness meditation intervention (IMMI), mindfulness meditation (MM), mindfulness-based cognitive therapy (MBCT), mindfulness-based stress reduction (MBSR) and mindfulness-based touch therapy (MBTT) met the inclusion criteria. The greatest effect sizes are reported in favour of MBTT, with SMDs of -1.138 (95%CI: -1.937 to -0.340; P = 0.005), followed by -1.003 (95%CI: -1.645 to -0.360; P = 0.002) for MBCT. SMDs of -0.618 (95%CI: -0.980 to -0.257; P = 0.001) and -0.551 (95%CI: -0.842 to -0.260; P < 0.0001) were reported for IMMI and MBSR in the pooling trials, respectively. Significant effects on sleep problem improvement are shown in all reviewed MBI programs, except MM, for which the effect size was shown to be non-significant. CONCLUSION All MBI programs (MBTT, MBCT, IMMI and MBSR), except MM, are effective options to improve sleep problems among people with depression or anxiety disorder.

show abstract

Meta-analysis: Second generation antidepressants and headache

Cited by 21 publications

References 106 publications

<p>Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study</p>

<p>Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study</p>

New Serotonin-Norepinephrine Reuptake Inhibitors and Their Anesthetic and Analgesic Considerations

Effects of mindfulness-based intervention programs on sleep among people with common mental disorders: A systematic review and meta-analysis

Contact Info

Product

Resources

About